A Proposal for the Optimal Management Target for Serum Non-High-Density Lipoprotein Cholesterol Level in Low-Risk Japanese Workers

Abstract

, the use of statins for the primary prevention of CVD events have resulted in a reduced risk of up to approximately 20%. These findings indicate the existence of substantial residual risk. Research has indicated remnant lipoproteins, i.e., intermediate metabolites of chylomicron and very-low-density lipoprotein, as major sources of IntroductionLarge-scale cohort studies have shown that the incidence of cardiovascular disease (CVD) increases with greater low-density lipoprotein cholesterol (LDLC) levels [1][2][3] . Furthermore, the efficacy of LDLClowering therapy via HMG-CoA reductase inhibitors

Relationship between Cardiorespiratory Fitness and Non-High-Density Lipoprotein Cholesterol: A Cohort Study

“…HDL-C and TG are likely to be intermediate factors for CRF; thus, this result may not indicate the effect of CRF accurately. Furthermore, the optimal management goal of non-HDL-C has been discussed 23 – 25 ) ; the same results as those in the main analysis were obtained by sensitivity analysis that examined the relationship between CRF levels and the incidence of a high level of non-HDL-C defined as a non-HDL-C level of ≥ 140 mg/dL, instead of ≥ 170 mg/dL ( p < 0.001) ( Supplementary Table 1 ). The same results as those in the main analysis were obtained by sensitivity analysis that excluded the participants with a high level of non-HDL-C within 2 years of the baseline ( p = 0.014) ( Supplementary Table 2 ).…”

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

“…If the TG level is ≥ 400 mg/dL, or if blood is collected after a meal, then the non-HDL-C target shall be used for the initial management of dyslipidemia instead of the LDL-C target. If non-HDL-C levels are used for screening in the general population, then it should also be noted that the difference between the non-HDL-C and LDL-C levels would be < 30 mg/dL, at approximately 20 mg/dL 349 , 350 ) . As in the previous guidelines, a TG level of < 150 mg/dL and an HDL-C level of ≥ 40 mg/dL are the recommended targets for both primary and secondary prevention.…”

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

“…Therefore, lifestyle modification should be the basic treatment after controlling LDL-C, non-HDL-C, and TG. the difference between non-HDL-C and LDL-C is smaller than 30 mg/dL and is usually around 20 mg/ dL 615,616) . On the other hand, as in the previous guideline, it is recommended that TG and HDL-C be managed with the goals of less than 150 mg/dL (fasting) and more than 40 mg/dL for primary and secondary prevention, respectively (less than 175 mg/ dL for non-fasting).…”